Neuropathic Pain Market
                     Neuropathic Pain Market Size, Share, Outlook, and Opportunity Analysis, 2020 - 2027
Neuropathic pain is a complex, chronic pain state that usually is accompanied by 
tissue injury. It may lead to damage, dysfunction, or injury of nerve fibers, 
thereby leading to misfiring of signals to other pain centers. The impact of a 
nerve fiber injury includes a change in nerve function both at the site of injury 
and areas around the injury.
The global neuropathic pain market is estimated to account for US$ 6,313.4 Mn in 
terms of value in 2019 and is expected to reach US$ 9,862.3 Mn by the end of 2027.
Browse Summary of the Research Report- 
https://www.coherentmarketinsights.com/market-insight/neuropathic-pain-market-3656
High prevalence of cancer is expected to boost growth of the global neuropathic 
pain market over the forecast period. For instance, according to the World Health 
Organization, around 18.1 million new cases and 9.6 million deaths were registered 
due to cancer worldwide in 2018. Moreover, increasing geriatric population is also 
expected to aid in growth of the market. For instance, according to the World 
Health Organization, geriatric population is expected to reach 2 billion by 2050, 
up from 900 million in 2015.
North America region held dominant position in the global neuropathic pain market 
in 2019, accounting for 35.9% share in terms of value, followed by 
Europe.Incomplete pain relief is expected to hinder growth of the global 
neuropathic pain market. For instance, use of strong opioids such as oxycodone in 
the treatment of neuropathic pain often leads to low reduction in pain.
Moreover, side-effects of medications are also expected to limit growth of the 
market. Use of opioids and steroids may lead to complications such as heart attack,
kidney failure, and damage in lungs.
High prevalence of neuropathic-like pain in psoriatic arthritis is expected to 
offer lucrative growth opportunities for players in the market. For instance, in 
July 2019, researchers from Cardiff University, U.K., reported that neuropathic-
like pain as evidence of abnormal pain processing is common in patients with 
psoriatic arthritis. Moreover, R&D in neuropathic pain is also expected to aid in 
growth of the market. For instance, in March 2020, researchers from Heidelberg 
University, Germany, reported assessment of the phytochemical composition and the 
possible prophylactic effects of an aqueous ethanol extract of Haematoxylon 
campechianum flowers on peripheral neuropathic pain in a chronic constriction 
injury rat model.
Anticonvulsants segment in the global neuropathic pain market was valued at US$ 
2,548.1 Mn in 2019 and is expected to reach US$ 4,310.3 Mn by 2027 at a CAGR of 
6.4% during the forecast period. Use of flavonoids can be effective in the 
treatment of neuropathic pain due to spared nerve injury, spinal nerve ligation, 
partial sciatic nerve injury, diabetes-induced neuropathy, chemotherapy-induced 
neuropathy, and chronic constriction injury.  
Several studies have demonstrated that electroacupuncture can be effective in 
decreasing neuropathic pain. For instance, in January 2020, researchers from 
Huazhong Agricultural University, China, demonstrated that Synaptotagmin 1 (Syt-1),
a synaptic vesicle protein for regulating exocytosis of neurotransmitters, impairs 
neuropathic pain and that electroacupuncture relieves neuropathic pain through 
down-regulating spinal Syt-1.
Major players operating in the global neuropathic pain market include, Pfizer, 
Inc., Johnson & Johnson Services, Inc., Sanofi S.A., Eily Lily and Company, 
GlaxoSmithKline PLC, Biogen Idec., Bristol-Myers Squibb, Baxter Healthcare 
Corporation, and Depomed, Inc.
Major players in the market are focused on approval and launch of new products in 
order to expand their product portfolio. For instance, in March 2020, Senzer 
Pharmaceuticals secured the Investigational New Drug application and data package 
for its ongoing FDA registration program from its former US strategic partner in 
order to get approval for its cannabinoid respiratory device for the treatment of 
side effects induced by anti-cancer treatments, specifically nausea, vomiting, and 
neuropathic pain.
Major players in the market are also focused on conducting clinical trials to 
expand their product portfolio. For instance, in February 2020, NoNO Inc., a 
privately-held biotechnology company, reported that novel peptide, nerinetide, 
without prior administration of alteplase, demonstrated medically important 
improvements in patients with acute ischemic stroke, in a multicenter, randomized, 
study.
Request A Sample Copy - https://www.coherentmarketinsights.com/insight/request-
sample/3656
Contact Us:
Mr. Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: [email protected]
*****************************************************************************